Eagle Eye Networks Forecasts Key Video Surveillance Trends for 2022

Businesses are turning to video surveillance to help them adapt and thrive amidst sustained disruptions and changes in the business environment

2022 Trends in Video Surveillance Report Released Today

The 2022 Trends in Video Surveillance report released today is a forecast for business leaders and owners who want to understand the physical security landscape and plan for success in 2022. The report is produced annually by Eagle Eye Networks.

AUSTIN, Texas, Nov. 30, 2021 (GLOBE NEWSWIRE) — Eagle Eye Networks, the global leader in cloud video surveillance, today released the 2022 edition of its annual Trends in Video Surveillance ebook, a forecast for business leaders and owners who want to understand the physical security landscape and plan for success in 2022.

“Almost two years into the global pandemic, businesses have experienced sustained disruptions in the supply chain, labor shortage challenges, and vast changes in workplace routines,” said Dean Drako, Eagle Eye Networks CEO. “Business owners’ reliance on video surveillance is increasing because the security and operational insights provided by video surveillance are helping them adapt to the new business environment. Concurrently, the emergence of artificial intelligence (AI) combined with cloud video surveillance promises better, faster, and more accurate analytics for security and business optimization. We expect businesses to rely even more on cloud-based AI analytics to help them thrive in 2022.”

To learn what the following five trends mean for your business, and more insights, download the free 2022 Trends in Video Surveillance ebook here.

Video Surveillance Trends for 2022:

  1. Businesses want the flexibility to add customized analytics to their video surveillance systems.
  2. Video surveillance will help businesses impacted by the labor shortage do more with less.
  3. More customers are understanding the business intelligence value of video surveillance.
  4. Pandemic trends around remote work and home and curbside delivery are here to stay.
  5. Interoperability is key to data management and security.

ABOUT EAGLE EYE NETWORKS
Eagle Eye Networks is the global leader in cloud video surveillance, delivering cyber-secure cloud-based video with artificial intelligence (AI) and analytics to make businesses more efficient and the world a safer place. The Eagle Eye Cloud VMS (video management system) is the only platform robust and flexible enough to power the future of video surveillance and intelligence. Eagle Eye is based in Austin, Texas with offices in Amsterdam, Bangalore, and Tokyo. Learn more at een.com.

EAGLE EYE PRESS CONTACT
GLOBAL HQ
Martha Entwistle
mentwistle@een.com
+1-512-473-0500

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a8872386-691a-4de9-8a92-f85f0e23865e

Instant Noodles Market Analysis By Key Players, Share, Revenue, Trends, Size, Growth, Opportunities, and Regional Forecast To 2026

Published by
Newstrail

The global instant noodles market size is projected to reach USD 65.77 billion by the end of 2026. The increasing demand for the product across the world will bode well for the market in the coming years. According to a report published by Fortune Business Insights, titled “Instant Noodles Market Size, Share & Industry Analysis, By Type (Chicken, Vegetable, Seafood, and Others), Ingredient (Oats, Rice, Wheat, and Others), Distribution Channel (Supermarkets/ Hypermarkets, Speciality Stores, Convenience Stores, and Online Retail), and Regional Forecast, 2019 – 2026,” the market was worth USD 41…. Continue reading “Instant Noodles Market Analysis By Key Players, Share, Revenue, Trends, Size, Growth, Opportunities, and Regional Forecast To 2026”

Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

4th approved indication for toripalimab

SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the National Medical Products Administration (NMPA) of China has approved its supplemental New Drug Application (sNDA) for toripalimab in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma (the “NPC”). This is the fourth approved indication for toripalimab in China. In December 2018, the NMPA granted a conditional approval to toripalimab for the second-line treatment of unresectable or metastatic melanoma. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy. In April 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

The sNDA is based on the JUPITER-02 study (NCT03581786), which is a randomized, double-blind, placebo-controlled and international multi-center Phase III clinical study led by Professor Ruihua Xu from Sun Yat-sen University Cancer Center. The results of the study showed that when compared with the standard first-line treatment of gemcitabine/cisplatin, toripalimab in combination with gemcitabine and cisplatin as the first-line treatment for patients with recurrent or metastatic NPC has better progression-free survival, higher objective response rate, longer duration of response and survival benefits regardless of PD-L1 expression status with a manageable safety profile. This study is the world’s largest Phase III clinical study for a checkpoint inhibitor in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC. The study results of JUPITER-02 were presented in the form of a Late-breaking Abstract (LBA) at the plenary session at the annual meeting of the American Society of Clinical Oncology (ASCO 2021) and were published as the cover article of the September 2021 issue of Nature Medicine.

“As the world’s first immuno-oncology (I-O) drug approved for the treatment of nasopharyngeal cancer (NPC), we continue to explore the potential of toripalimab in different settings within NPC and across other cancer types, with the support of patients, investigators and our research team participating in clinical trials. We have now received approval for a new indication for toripalimab with chemotherapy for the first-line treatment of NPC, which provides better treatment outcomes for more patients with advanced NPC,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “Junshi Biosciences focuses on tumor types that are 1) highly prevalent in China; 2) responsive to immunotherapy; and 3) where there is urgent unmet need for better and safer treatments. The results of POLARIS-02 and JUPITER-02 studies for NPC are representative examples of our clinical program. We are delighted to see that the breakthrough results obtained with toripalimab not only bring new hope to Chinese patients, but also earn international recognition from academia and regulatory authorities. We hope that our novel I-O drug will be available to benefit patients outside China in the near future.”

About Nasopharyngeal Carcinoma
NPC is a primary malignant tumor of the nasopharyngeal mucosal epithelium, which is one of the most common head and neck cancers. According to the World Health Organization, the number of newly diagnosed NPC cases in 2020 exceeded 130,000 worldwide, and nearly half of the cases occurred in China. The current therapies are limited for recurrent or metastatic NPC. The first-line standard therapy is platinum-based dual-drug combination chemotherapy. The overall survival of the patients is poor.

About Toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 is thought to recharge the immune system’s ability to attack and kill tumor cells. More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). On December 17, 2018, toripalimab was granted a conditional approval by the National Medical Products Administration (NMPA) for the second-line treatment of unresectable or metastatic melanoma. In December 2020, toripalimab was successfully included in the updated National Reimbursement Drug List. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (“NPC”) after failure of at least two lines of prior systemic therapy. In April, the NMPA granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. In November 2021, the NMPA approved toripalimab in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma. In addition, the supplemental NDA for the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma was accepted by the NMPA for review in July 2021.

In the United States, the FDA has granted priority review for the toripalimab BLA for the treatment of recurrent or metastatic NPC, an aggressive head and neck tumor which currently has no FDA-approved immuno-oncology treatment options. Earlier, the FDA granted Breakthrough Therapy designation for toripalimab in combination with chemotherapy for the 1st line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and orphan drug designation for esophageal cancer, NPC, mucosal melanoma and soft tissue sarcoma. Earlier in 2021, Coherus in-licensed rights to develop and commercialize toripalimab in the United States and Canada. Coherus and Junshi Biosciences plan to file additional toripalimab BLAs with the FDA over the next three years for multiple other cancer types.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 45 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in 15 countries and regions worldwide. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Bright Peak Therapeutics Appoints Jacob Chacko, M.D., as Chair of its Board of Directors

SAN DIEGO and BASEL, Switzerland, Nov. 29, 2021 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it has appointed Jacob Chacko, M.D., as Chair of its Board of Directors. Dr. Chacko currently serves as President, CEO and member of the Board of Directors of ORIC Pharmaceuticals, Inc., (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance.

“Jacob is an accomplished life-science executive and highly regarded board member with a track record of building leading oncology-focused biotechnology companies,” said Fredrik Wiklund, President and CEO of Bright Peak. “Jacob will bring scientific insights and a wealth of experience in corporate and financial strategy to Bright Peak during an important time in the company’s continued evolution.”

“We welcome Jacob to the Board and look forward to his many contributions to Bright Peak’s future success,” said Dr. Tom Woiwode, Managing Director of Versant Ventures and Bright Peak Board member. “He is the perfect fit for the company’s next stage of growth, given his substantial biotech company leadership experience.”

“I’m excited to join Bright Peak’s Board of Directors and look forward to working alongside the executive team and my fellow board members to build a leading biotechnology company delivering novel and disease-modifying immunotherapies for patients suffering from cancer and autoimmune disorders,” said Dr. Chacko.

Dr. Chacko has served as CEO of ORIC Pharmaceuticals since April 2018. During Dr. Chacko’s tenure, ORIC has raised over $375mm in private and public financing, including its IPO in April 2020, has advanced its lead program into two Phase 1b trials, has in-licensed two additional programs, and is on track to file three INDs/CTAs in 2021. Prior to ORIC, Dr. Chacko was most recently CFO of Ignyta, a Nasdaq-listed precision oncology company acquired by Roche for $1.9 billion in February 2018. At Ignyta, he had a broad operational role and helped raise over $500 million in capital. Prior to Ignyta, Dr. Chacko was an investor at TPG Capital, where he helped lead teams that completed acquisitions having an aggregate value of over $10 billion. Prior to that, he was a consultant serving healthcare clients at McKinsey & Company.

Dr. Chacko currently serves on the board of directors of 4D Molecular Therapeutics (Nasdaq: FDMT) and chairs the Western Regional Selection Committee for the Marshall Scholarship. He previously served on the board of directors of Turning Point Therapeutics, Bonti (acquired by Allergan), EnvisionRx (acquired by Rite Aid), RentPath, and the Packard Children’s Health Alliance at the Lucile Packard Children’s Hospital Stanford; and he was a board observer to Par Pharmaceutical (acquired by Endo), IMS Health and Quintiles Transnational.

Dr. Chacko concurrently received his MD with AOA honors from UCLA and his MBA with Distinction from Harvard Business School. He also received a MSc from Oxford University as a Marshall Scholar and undergraduate degrees from the University of Southern California, where he graduated as the University Valedictorian.

About Bright Peak

Bright Peak is a privately held biotechnology company based in San Diego, USA and Basel, Switzerland dedicated to creating next-generation cytokine immunotherapies for the treatment of patients with cancer and autoimmune disease. Bright Peak is pioneering a novel technology to chemically synthesize enhanced and conjugatable cytokines that exploits the potent biological activity of cytokines while avoiding the severe side effects associated with first-generation therapies. Bright Peak’s enhanced cytokines can be easily conjugated to a diverse array of molecules, such as monoclonal antibodies, creating a novel class of “Bright Peak Immunocytokines”. Bright Peak is funded by a syndicate of leading healthcare investors.

Contact:
info@brightpeaktx.com

Banks allowed to extend credit growth quota

The State Bank of Vietnam (SBV) has extended the credit growth limits for the third time this year to some commercial banks to meet rising capital demands at year-end.

According to a report from the Bank for Investment and Development of Vietnam’s Securities Company (BSC), 11 banks have been given permission to increase their credit growth limit.

TPBank has the highest rising rate of 6 percent, from 17.4 percent to 23.4 percent, thanks to its strong capital adequacy ratio (CAR) according to Basel II standards and diverse investment portfolio.

In addition to TPBank, a number of other banks were allowed to expand their credit room by roughly 4-5 percent, including Techcombank (from 17.1 percent to 22.1 percent), MSB (from 16 percent to 22 percent) and MB (from 15 percent to 21 percent).

Credit room of VIB and VPBank was also expanded from 14.1 percent to 19.1 percent, and from 12.1 percent to 17.1 percent, respectively.

The SBV stated in its monetary policy management solutions for the last three months of the year that it will periodically assess and modify credit growth objectives for each bank based on its operational status, financial capacity and stability of credit expansion.

According to Nguyen Tuan Anh, head of the SBV’s Credit Department, credit growth rates were granted based on the particulars of each bank.

Moreover, banks that do not focus on hazardous and vulnerable businesses, with favourable interest rates are gaining the upper hand in terms of credit quota.

As a result, credit institutions that lower lending interest rates to support affected clients will be given priority consideration.

At the beginning of 2021, the SBV outlined three credit growth scenarios for the year.

The first scenario posits widespread COVID-19 vaccine coverage and the containment of the pandemic. This could see credit increases of 12-13 percent, perhaps even 14 percent.

In the second scenario, if the pandemic lasts until June, social distancing measures are still in place and vaccination rollout is prolonged, the rate could stand at 10-12 percent.

The third scenario suggests that credit growth could be at 7-8 percent if the pandemic lasts through the end of the year.

According to Anh, events so far are most similar to the third scenario as Vietnam suffers from the fourth outbreak of the COVID-19 pandemic.

However, credit growth in the first half of the year was far beyond the SBV’s expectation thanks to modest loan interest rates. As of June 21, the growth rate was 5.47 percent, considerably higher than the 2.45 percent over the same period last year.

The Asia Commercial Bank’s Securities Company forecast credit growth this year to be at 14 percent, equivalent to the highest rate in the best-case scenario, noting that it may even reach 15-20 percent among private banks.

ACB expects that credit demand will stay strong and credit growth will remain high in the second half of 2021, especially during the fourth quarter.

Source: Vietnam News Agency

Vietnam attends 59th meeting of Asian – African Legal Consultative Organisation

Minister of Foreign Affairs Bui Thanh Son, officials from the ministries of Public Security and Justice, and some researchers and practitioners of international law in Vietnam are attending the 59th meeting of the Asian – African Legal Consultative Organisation (AALCO) via videoconference.

The Vietnamese delegation delivered speeches which highlight international law, respect for the rule of law at the international level, and support for the peaceful settlement of international disputes.

They also shared the country’s experience in handling external relations, as well as its viewpoints on the codification and progressive development of international law, according to the Foreign Ministry.

The AALCO, comprising 47 member states, is an international inter-governmental organisation established in 1956 in the Non-Aligned Movement of Asia and Africa. It aims to promote dialogue, exchange viewpoints, and enhance cooperation in many areas of international law.

Taking place from November 29 to December 1, this year’s event in Hong Kong (China) focuses on such legal issues as activities of the International Law Commission and international law in cyberspace. It is set to elect the AALCO Secretary-General for the 2021 – 2025 tenure.

Vietnam officially became an AALCO member at this organisation’s 56th meeting in Kenya in 2017 after serving as an observer for a period of time.

Source: Vietnam News Agency

Agricultural sector forecast to exceed annual export target for 2021

The Ministry of Agriculture and Rural Development (MARD) expects to exceed its annual export target for agricultural, forest and fishery products, thanks to the restoration of production and business after the COVID-19 outbreak.

“This year, MARD has predicted that the export turnover of agricultural, forest and fishery products to reach over 44 billion USD, exceeding its initial target of 42 billion USD,” said Phung Duc Tien, Deputy Minister of Agriculture and Rural Development.

According to the Minister of Agriculture and Rural Development, Le Minh Hoan, there will be many export opportunities for local agricultural products in the fourth quarter of 2021, especially over Christmas and New Year of 2022 and the Lunar New Year.

The European market will be a big destination for Vietnamese agricultural products and strong trade with the Thai, South American, African markets is expected to continue, he said.

“I hope that the Government’s existing policies, along with the initiatives of localities, will encourage exporting enterprises to restore their trading activities,” Hoan said.

To seize opportunities to recovery and increase exports of agricultural, forestry and fishery products by this year-end, MARD will coordinate with ministries and sectors to implement trade promotion programmes that focus on opening new export markets, according to Nguyen Quoc Toan, Director of the Department of Agricultural Product Processing and Market Development.

They will also provide businesses with market information and regulations on goods that are traded between Vietnam and China, and quotas for local agricultural products under the EVFTA and UKVFTA agreements.

This year exports of agricultural, forestry and fishery products have faced many challenges caused by the COVID-19 pandemic. In particular, the fourth outbreak that began in late April led to disruption across the economy, impacting farm produce supply chains, production and export activities nationwide, according to MARD.

The agriculture industry has maintained export growth for many products in both quantity and value. In the first ten months of this year, the export value of agricultural, forestry and fishery products was estimated at 38.8 billion USD, up 13.1 percent over the same period in 2020, the ministry said.

Nudging closer to the target of 44 billion USD in export value for this whole year, the sector’s export turnover reached at least 5.2 billion USD in the last two months, according to the ministry.

This is a great success in the context of the complicated development of the pandemic that has disrupted the supply chains of agricultural raw products, directly affecting the processing and export of agricultural, forestry and aquatic products.

The disruption in the supply chain of agricultural products is due to localities implementing the Government’s regulations on prevention and control of the COVID-19 in different ways, according to Tien.

He also believes that the Government’s goal of recovering economic development may face some difficulties if the pandemic continues to reemerge in new localities.

Agricultural development faces challenges from other areas too; crop and animals diseases, climate change, natural disasters, drought and saltwater intrusion also continue to negatively affect production.

Other problems include the slow recovery of production chains, a lack of labour and the congestion in transporting agricultural, forestry and fishery products. Many processing enterprises are also short of the capital needed to continue production and business. Others have not yet met the material conditions to maintain production.

Higher freight along some routes and an increase in the price of animal feed and fertiliser have also created more difficulties for enterprises.

MARD plans to help restore agricultural development through the Government policies that were issued after the COVID-19 outbreak. MARD and the Ministry of Industry and Trade are coordinating to reduce inventories of agricultural products and ensure supply for the export agricultural products. They will also have solutions to reduce the price of input materials that have increased recently.

“The higher input price in Vietnam is caused by an increase in prices around the world, due to the COVID-19 pandemic. Agricultural input in the country depends on imports, which accounts for 70-80 percent of demand. If imports are interrupted due to transportation difficulties, this will lead to a shortage of input material on the domestic market,” Tien remarked.

The two ministries have recommended that the Government produce policies that encourage the domestic production of input materials and introduce a mechanism that cuts the volume of export commodities that could be used for raw material production in the future.

It has also been suggested that farmers be more conservative with their input materials usage, as often they use more input materials than is needed. If farmers can adapt to using only what they need, it could reduce usage by up to 40 percent.

In addition, to restore supply chains, the agriculture sector has proposed that the Ministry of Health increase the number of vaccines available to industry workers, as farming products must be transported across many regions.

According to Tien: “In the future, Vietnam’s agriculture sector must ensure seeds and input material as well diversifying markets and products. The sector also needs to build raw material areas and supply chains based on enterprises and cooperatives, meeting standards of export markets.”

Dinh Cao Khue, Chairman of the Dong Giao Foodstuff Export Joint Stock Company (DOVECO), an enterprise that exports agricultural products and fruits to 55 countries, said that his company has maintained exports during the fourth outbreak of COVID-19.

“We have faced many difficulties, especially in purchasing and transporting raw materials as many localities have applied social distancing measures to control the pandemic, according to Directive 16,” said Khue.

At the same time, the cost of exporting to the US and European markets continues to rise compared to before the pandemic, which is creating financial pressure on exporting enterprises.

Despite this, Nguyen Dinh Tung, General Director of Vina T&T Group, argues that: “the last months of the year are an opportunity for fruit export, as fruit demand is highest in those months for festivals at the end of the year and the early next year. We hope to increase the volume of exports because of increasing orders from partners.”

Ngo Tuong Vy, Deputy Director of Chánh Thu Fruit Import-Export Co, Ltd, said that to increase capacity to export key fruit products, her company will purchase more mangoes, durian and jackfruit in Dong Thap. These are key export products; mangoes for the US and Australia, jackfruit for China and durian for China, Japan and Australia.

To help meet demand, Vy’s company will support cooperatives in technical consulting, the building of raw material regions and the establishment of production and supply chains to create a stable supply of exports, she said.

Nguyen Hai Nam, Chairman of the Vietnam Pepper Association, said the pepper industry has quickly restored production and business after the COVID-19 outbreak. They expect to gain growth in both quantity and value of pepper exports this year due to convenience in transporting raw materials.

Source: Vietnam News Agency

There remains large room for exports to US: Official

The US remains a promising market of Vietnam and there remained large room for more exports, Minister Counsellor Bui Huy Son of the Vietnam Trade Office in the US told a consultation session on export to the US held via conference on November 30.

Son said the US is importing more Vietnamese farm produce, food and wooden furniture. Between 2021-2025, its demand for food and farm produce is forecast to keep rising.

In the remaining months of this year, the prospect of exporting wooden furniture to the US is bright on the back of growing shopping demand during holidays, he said.

Deputy Director of the Ministry of Industry and Trade’s Vietnam Trade Promotion Agency Le Hoang Tai said the US economy is recovering strongly with a gross domestic product growth of 4.9 percent in the third quarter this year. Despite the pandemic, two-way trade between Vietnam and the US is about to hit 100 billion USD in 2021.

As online shopping trend is becoming popular, several opinions suggested tapping major e-commerce sites such as Amazon to introduce products. Therefore, firms need to make difference via design or marketing strategies.

In order to help Vietnamese goods successfully enter the US market, they were advised to ensure the origin of materials and step up trade promotion activities.

Experts instructed them how to set up a distribution system, accelerate the use of advanced technologies and actively link up with Vietnamese business associations in US states.

Source: Vietnam News Agency